Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOUQUET biomarker-driven platform study in recurrent rare epithelial ovarian tumors
2023-508194-89-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib, ipatasertib, inavolisib, olaparib, giredestrant and 8 more in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Roche. Primary endpoint: Confirmed objective response rate. Planned start Aug 2021; status: authorised.
02
Drugs
abemaciclibipatasertibinavolisibolaparibgiredestrant
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2023-508194-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508194-89-00.